Given that early therapy can improve survival in CGD, the prompt identification of atypical X-linked CGD variants with residual NADPH oxidase, in cases such as our patient, can significantly impact the clinical outcome of children with this condition. Here, FMO5 is linked to chronic granulomatous disease.